Conditions: Peripheral Artery Disease
Keywords: Peripheral artery disease Intermittent claudication magnetic resonance imaging
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 38
Healthy volunteers: no

Brief summary:
This study was designed to assess the safety, tolerability and efficacy of ACZ885 on the leg artery structure and physical activity in patients with atherosclerotic peripheral artery disease and leg pain from walking.

Detailed description:

Arms:
arm 1: Monthly subcutaneous doses of Canakinumab 150 mg/1 mL for 12 months arm 2: Monthly subcutaneous doses of placebo of Canakinumab 150 mg/1 mL for 12 months

Interventions: intervention 1: Canakinumab (ACZ885) intervention 2: Placebo
Intervention descriptions: intervention 1: Dosage form: solution for injection Strength: 150 mg/1 mL Mode of administration: subcutaneous use. intervention 2: Matching placebo of Canakinumab

Protocol document: